Medical technology company benefits from currency effects / Earnings impacted by special effects

Carl Zeiss Meditec AG looks back on another positive fiscal year: boosted by positive currency effects, the medical technology company's revenue passed the billion mark in fiscal year 2014/15, with a 14 percent increase to € 1,040 million. Adjusted for currency effects, this equates to growth of around 8 percent over the prior year. Earnings before interest and taxes (EBIT) increased by 8 percent, to € 130.6 million (prior year: € 120.7 million)...

Illumina invests in Desktop Genetics’ technology to support the platform’s integration with NGS pipelines and improve CRISPR genome editing workflows

Desktop Genetics Ltd (“DTG” or “the Company”), a software company revolutionizing the way biologists use CRISPR gene editing technology, announced today that it has received investment funding from Illumina, Inc. (NASDAQ: ILMN), the global leader in next-generation sequencing (NGS) technology. The investment will be used to fund the continued development and commercialization of the DESKGEN platform with a particular focus on integration with NGS pipelines. The investment from Illumina follows DTG’s recent fundraising from a syndicate of...

The Genome Analysis Centre (TGAC) is delighted to announce the appointment of Professor Neil Hall as its new Director.

Professor Neil Hall will join TGAC in April 2016 from the University of Liverpool where he is currently the Director of The Centre for Genomic Research. As a leader in the field of genomics, Professor Hall has specialised in understanding the genomics of infectious disease over the past decade. He has led projects at The Wellcome Trust Sanger Institute and The Institute for Genomic Research (TIGR) in the US, including the effort to

One World Lab has announced a strategic partnership with Tonbo Biosciences meaning a complete offering of primary antibodies in a conjugated format are now available at www.oneworldlab.com.

Researchers now have access to a full resource of flow cytometry antibodies that are manufactured to the highest quality and precision, resulting in consistently high performance. In line with the One World Lab model, these antibodies are offered in test sized aliquots allowing researchers the flexibility to test multiple antibodies more cost efficiently. Conjugated primary antibodies are extremely useful reagents for studies in a number of...

The European Investment Bank, Europe’s long-term lending institution, has agreed to provide GBP 107m to support construction of the new Midland Metropolitan Hospital in Birmingham.

Once open in three years’ time the brand new hospital will provide state of the art acute healthcare for 530,000 people living in Sandwell and West Birmingham and include one of the largest accident and emergency departments in Europe. The new hospital scheme, costing GBP 340m, includes 670 beds and 15 operating theatres, as well as a new public park, reached financial close following an agreement between the Sandwell...

The University of Nottingham, a long-standing customer of UK flowmeter specialist Litre Meter, has ordered further Smart-Trak high-performance digital mass flow controllers to measure the flow of gases used in biomolecular research.

The latest order forms part of a supply relationship between Litre Meter and the Centre for Biomolecular Sciences at the University of Nottingham (CBS) dating back more than 20 years. During that time Litre Meter has supplied various flowmeters for a number of research applications and undertaken calibration services as required. Litre Meter has most recently supplied a range of Smart-Trak? 100 Series instruments designed to measure flow ranges...

The latest software release along with an expansion of the global technical specialist team, highlight Malvern Instruments’ ongoing commitment to extending and supporting the application of NanoSight, a nanoparticle characterization technology with unique capabilities.

The Malvern NanoSight range enables the visualization, sizing and counting of nanoparticles, exosomes, protein aggregates, and is increasingly being used in biopharma and nanoparticle research. “Two years on from joining Malvern, the benefits of becoming part of a larger global business are clear. NanoSight customers are now benefiting directly from Malvern’s highly developed skills in making complex analytical techniques more...

EU study to build on Phase I trial of Videregen product & generate approval application

The pan-European TETRA consortium, led by Videregen Limited, has been awarded EUR 6.8 million under the Horizon 2020 programme[1] for a pivotal Phase II clinical trial of the company's tissue engineered replacement trachea. The project will start at the beginning of 2016 with the first patients to be treated in 2017, building on the results of the four-patient UK INSPIRE Phase I study[2] The study will focus on the orphan indication...

The company aims to advance NOSO-95179, a promising antibacterial compound, to clinical stage for the treatment of multidrug-resistant Gram-negative infections

Nosopharm, a biotechnology company specialized in the research and development of new antibacterial molecules, today announces it has been selected to join ENABLE (European Gram-negative Antibacterial Engine), a project working to advance the development of potential antibiotics against multidrug resistant Gram-negative infections. ENABLE is one of seven projects in the New Drugs For Bad Bugs (ND4BB) consortium, part of the Innovative Medicines...

Demand drives expansion of Titian's team, underlining the global success of its Mosaic software

Titian Software, has announced the appointments of James Craven, head of global marketing, and Angela Gray, Western US sales manager, to further consolidate its position as the world leader in sample management software. The successful launch earlier this year of Titian’s Mosaic Freezer Management, a cost-effective software package optimised for small to medium-sized sample collections, followed the recent introduction of Titian’s Mosaic...

NHS Wales Shared Services Partnership, on behalf of Betsi Cadwaladr University Local Health Board, contracted with Leica Biosystems for its Aperio digital pathology solutions.

This partnership has enabled the merging of three sites: Glan Clwyd, Wrexham & Bangor to form the new trust: North Wales. Digital pathology enables rapid distribution, eliminating slide shipping costs and travel time. Additionally, the digital slides can be annotated to facilitate a more efficient and accurate review from one pathologist to another. The use of digital pathology is leveraging NHS Wales as a pioneering healthcare organization...

Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has today announced that it will join the MATURA Consortium.

The overarching mission of the MATURA Consortium is to improve patient care in Rheumatoid Arthritis (RA) by rationalizing therapy decisions through a stratified medicine approach.

MATURA (MAximising Therapeutic Utility for Rheumatoid Arthritis) aims to identify treatment response predictors which will allow the allocation of patients to subgroups defined by the therapy they are most likely to respond to, early in the disease process. RA provides the ideal setting for the introduction of a stratified medicine approach as the treatment is standardized, there is a significant non-responder rate to each marketed and commonly used drug, and early and effective therapy has consistently been shown to improve long-term outcomes, including joint damage, disability and employment.

Acquisition increases capacity to deliver high quality, locally manufactured oligos.

Integrated DNA Technologies, the global leader in custom nucleic acid synthesis, has entered into a definitive agreement to acquire the oligonucleotide synthesis business of AITbiotechPte. Ltd. in Singapore (“AITbiotech”). With this acquisition, IDT expands its customer base across Southeast Asia making it possible for these additional customers to now have access to its broad range of products for genomic applications. AITbiotech will...

Quotient Clinical the Translational Pharmaceutics® company, has announced that it has been acquired by specialist healthcare investor GHO Capital, with financial details of the transaction remaining undisclosed.

Quotient Clinical has brought innovation to the drug development process through its unique Translational Pharmaceutics® platform, which integrates formulation development, real-time GMP manufacturing and clinical testing. This approach has been proven to accelerate timelines and reduce associated costs, driving overall improvements in R&D productivity. With over 280 employees, the company serves an international customer...

Cell counting and analysis just got easier and better

Eikonix are pleased to announce that they have been appointed by Countstar to sell their automated cell counters and fluorescence cell analyser in the UK. Featuring ease of use, efficiency, accuracy and reliability, these products have been widely used in major research and medical institutions in various fields including biopharmaceuticals, beer and beverages.

Key achievements include facilities, research and development, partnerships and recruitment

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the release of their 2015 Annual Review. The second review covers the 12 months from April 2014 to 2015, during which the Cell Therapy Catapult...

New Report Available

The World Market for Liquid Chromatography in Healthcare, provides useful business planning information and competitive analysis for this particular industry, including Market Size, Forecast, Research and Clinical Markets, Market Share, Analyst Commentary and Corporate Profiles. This is slow-evolving industry but recently, new technologies and applications are providing change in the market. The report covers these trends in detail...

MR Solutions and Summit Pharmaceuticals have reached an agreement where Summit Pharmaceuticals will be the sole supplier for MR Solutions’ preclinical, multi-modality cryogen free MRI imaging systems to the Japanese market.

Summit Pharmaceuticals, part of the Sumitomo Corporation, is a leading Japanese provider of drug discovery instruments and through this partnership, both companies will be able to offer a complete imaging portfolio of high field preclinical multi-modality MRI solutions including PET/MR and SPECT/MR, plus CT, optical systems, and bioresource materials. Based in Surrey, UK, MR Solutions pioneered the development of the world’s...

Frost & Sullivan Recognizes Potential for its ‘Groundbreaking’ Functionality

Medtech innovator Medimetrics has won the 2015 Frost & Sullivan Award for ‘Product Innovation in Personalized Drug Delivery’ for its IntelliCap micro-electronics, oral drug delivery system. The award is open to companies trading in North America.IntelliCap enables the pre cise delivery of drugs in the gastro-intestinal tract and the measurement and reporting of conditions in the body. The official Frost & Sullivan report...

As part of the annual awards ceremony for the Lifetime Business Achievement Medal of Honor event, the Secretary of State for Trade and Industry Nils Shmid presented Gerhard Juchheim with the Lifetime Business Achievement Medal of Honor for 2015 from the state of Baden-Württemberg.

Since 1978 this award has been bestowed on leaders and companies for their outstanding professional and entrepreneurial achievements. Gerhard Juchheim was honored for his lifetime business contribution in Baden-Württemberg by Mr. Schmid in the famous marble ballroom of the Neuen Schloss (New Castle) in Stuttgart. It was an honor not only for Gerhard Juchheim but also for the long-standing historical tradition of this family company...

Re-Pharm, an early-stage drug discovery and development company based on the principles of compound re-profiling, is pleased to announce that they have been awarded a GB patent on the re-purposed compound RP0217 for the treatment of inflammatory disorders.

This patent protects the topical use of RP0217 for the treatment or prevention of respiratory and gastrointestinal inflammatory disorders, including rhinitis, asthma, chronic obstructive pulmonary disease, ulcerative colitis, and Crohn’s disease. “Patients with chronic inflammation typically rely on steroids to control their disorders,” explains Dr Robert Scoffin, CEO of Re-Pharm. “We are delighted to have identified this non-steroidal alternative...

Gel Company celebrates 20 years of serving the life science market. Founded in 1995, Gel Company, based in San Francisco, develops manufactures, and supplies low cost products to the life science research community.

The company has set its goal to provide innovative, high quality products with an efficient, friendly service. The aim of Gel Company is to offer all its products at competitive prices. The focus is to develop, manufacture and supply innovative tools for proteomics, genomics, cell biology, liquid handling and microarray applications to scientists around the world.